An economic evaluation of rosuvastatin treatment in systolic heart failure: Evidence from the CORONA trial

Paula K. Lorgelly, Andrew H. Briggs, Hans Wedel, Peter Dunselman, AKe Hjalmarson, John Kjekshus, Finn Waagstein, John Wikstrand, A. Jánosi, Dirk J. Van Veldhuisen, Vivencio Barrios, Cândida Fonseca, John J V McMurray

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Aims: To estimate the cost-effectiveness of 10 mg rosuvastatin daily for older patients with systolic heart failure in the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) trial.Methods and resultsThis within trial analysis of CORONA used major cardiovascular (CV) events as the outcome measure. Resource use was valued and the costs of hospitalizations, procedures, and statin use compared. Cost-effectiveness was estimated as cost per major CV event avoided. There were significantly fewer major CV events in the rosuvastatin group compared with the placebo group (1.04 vs. 1.20 per patient; difference 0.164; 95 CI: 0.075-0.254, P <0.001). The average cost of CV hospitalizations and procedures was significantly lower for those receiving rosuvastatin (£1531 vs. £1769; difference £238; 95 CI: £73-403, P = 0.005); the additional cost of the statin resulted in significantly higher total costs for the rosuvastatin group (£1769 vs. £2072; difference £303; 95 CI: £138-468, P <0.001). Overall, rosuvastatin was found to cost £1840 (95 CI: £562-6028) per major CV event avoided.ConclusionThis economic analysis showed that a significant reduction in major CV events with rosuvastatin led to significantly reduced costs of CV hospitalizations and procedures. The reduction in associated costs for major CV events was found to offset partially (by 44) the cost of rosuvastatin treatment in patients with systolic heart failure.

Original languageEnglish
Pages (from-to)66-74
Number of pages9
JournalEuropean Journal of Heart Failure
Volume12
Issue number1
DOIs
Publication statusPublished - Jan 2010

Fingerprint

Systolic Heart Failure
Cost-Benefit Analysis
Costs and Cost Analysis
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hospitalization
Therapeutics
Rosuvastatin Calcium
Health Care Costs
Heart Failure
Placebos
Economics
Outcome Assessment (Health Care)

Keywords

  • Cost-effectiveness
  • Heart failure
  • Multinational trial
  • Statins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Lorgelly, P. K., Briggs, A. H., Wedel, H., Dunselman, P., Hjalmarson, AK., Kjekshus, J., ... McMurray, J. J. V. (2010). An economic evaluation of rosuvastatin treatment in systolic heart failure: Evidence from the CORONA trial. European Journal of Heart Failure, 12(1), 66-74. https://doi.org/10.1093/eurjhf/hfp172

An economic evaluation of rosuvastatin treatment in systolic heart failure : Evidence from the CORONA trial. / Lorgelly, Paula K.; Briggs, Andrew H.; Wedel, Hans; Dunselman, Peter; Hjalmarson, AKe; Kjekshus, John; Waagstein, Finn; Wikstrand, John; Jánosi, A.; Van Veldhuisen, Dirk J.; Barrios, Vivencio; Fonseca, Cândida; McMurray, John J V.

In: European Journal of Heart Failure, Vol. 12, No. 1, 01.2010, p. 66-74.

Research output: Contribution to journalArticle

Lorgelly, PK, Briggs, AH, Wedel, H, Dunselman, P, Hjalmarson, AK, Kjekshus, J, Waagstein, F, Wikstrand, J, Jánosi, A, Van Veldhuisen, DJ, Barrios, V, Fonseca, C & McMurray, JJV 2010, 'An economic evaluation of rosuvastatin treatment in systolic heart failure: Evidence from the CORONA trial', European Journal of Heart Failure, vol. 12, no. 1, pp. 66-74. https://doi.org/10.1093/eurjhf/hfp172
Lorgelly, Paula K. ; Briggs, Andrew H. ; Wedel, Hans ; Dunselman, Peter ; Hjalmarson, AKe ; Kjekshus, John ; Waagstein, Finn ; Wikstrand, John ; Jánosi, A. ; Van Veldhuisen, Dirk J. ; Barrios, Vivencio ; Fonseca, Cândida ; McMurray, John J V. / An economic evaluation of rosuvastatin treatment in systolic heart failure : Evidence from the CORONA trial. In: European Journal of Heart Failure. 2010 ; Vol. 12, No. 1. pp. 66-74.
@article{0a37bc2e448f4d15beb08c240a7e833b,
title = "An economic evaluation of rosuvastatin treatment in systolic heart failure: Evidence from the CORONA trial",
abstract = "Aims: To estimate the cost-effectiveness of 10 mg rosuvastatin daily for older patients with systolic heart failure in the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) trial.Methods and resultsThis within trial analysis of CORONA used major cardiovascular (CV) events as the outcome measure. Resource use was valued and the costs of hospitalizations, procedures, and statin use compared. Cost-effectiveness was estimated as cost per major CV event avoided. There were significantly fewer major CV events in the rosuvastatin group compared with the placebo group (1.04 vs. 1.20 per patient; difference 0.164; 95 CI: 0.075-0.254, P <0.001). The average cost of CV hospitalizations and procedures was significantly lower for those receiving rosuvastatin (£1531 vs. £1769; difference £238; 95 CI: £73-403, P = 0.005); the additional cost of the statin resulted in significantly higher total costs for the rosuvastatin group (£1769 vs. £2072; difference £303; 95 CI: £138-468, P <0.001). Overall, rosuvastatin was found to cost £1840 (95 CI: £562-6028) per major CV event avoided.ConclusionThis economic analysis showed that a significant reduction in major CV events with rosuvastatin led to significantly reduced costs of CV hospitalizations and procedures. The reduction in associated costs for major CV events was found to offset partially (by 44) the cost of rosuvastatin treatment in patients with systolic heart failure.",
keywords = "Cost-effectiveness, Heart failure, Multinational trial, Statins",
author = "Lorgelly, {Paula K.} and Briggs, {Andrew H.} and Hans Wedel and Peter Dunselman and AKe Hjalmarson and John Kjekshus and Finn Waagstein and John Wikstrand and A. J{\'a}nosi and {Van Veldhuisen}, {Dirk J.} and Vivencio Barrios and C{\^a}ndida Fonseca and McMurray, {John J V}",
year = "2010",
month = "1",
doi = "10.1093/eurjhf/hfp172",
language = "English",
volume = "12",
pages = "66--74",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - An economic evaluation of rosuvastatin treatment in systolic heart failure

T2 - Evidence from the CORONA trial

AU - Lorgelly, Paula K.

AU - Briggs, Andrew H.

AU - Wedel, Hans

AU - Dunselman, Peter

AU - Hjalmarson, AKe

AU - Kjekshus, John

AU - Waagstein, Finn

AU - Wikstrand, John

AU - Jánosi, A.

AU - Van Veldhuisen, Dirk J.

AU - Barrios, Vivencio

AU - Fonseca, Cândida

AU - McMurray, John J V

PY - 2010/1

Y1 - 2010/1

N2 - Aims: To estimate the cost-effectiveness of 10 mg rosuvastatin daily for older patients with systolic heart failure in the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) trial.Methods and resultsThis within trial analysis of CORONA used major cardiovascular (CV) events as the outcome measure. Resource use was valued and the costs of hospitalizations, procedures, and statin use compared. Cost-effectiveness was estimated as cost per major CV event avoided. There were significantly fewer major CV events in the rosuvastatin group compared with the placebo group (1.04 vs. 1.20 per patient; difference 0.164; 95 CI: 0.075-0.254, P <0.001). The average cost of CV hospitalizations and procedures was significantly lower for those receiving rosuvastatin (£1531 vs. £1769; difference £238; 95 CI: £73-403, P = 0.005); the additional cost of the statin resulted in significantly higher total costs for the rosuvastatin group (£1769 vs. £2072; difference £303; 95 CI: £138-468, P <0.001). Overall, rosuvastatin was found to cost £1840 (95 CI: £562-6028) per major CV event avoided.ConclusionThis economic analysis showed that a significant reduction in major CV events with rosuvastatin led to significantly reduced costs of CV hospitalizations and procedures. The reduction in associated costs for major CV events was found to offset partially (by 44) the cost of rosuvastatin treatment in patients with systolic heart failure.

AB - Aims: To estimate the cost-effectiveness of 10 mg rosuvastatin daily for older patients with systolic heart failure in the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) trial.Methods and resultsThis within trial analysis of CORONA used major cardiovascular (CV) events as the outcome measure. Resource use was valued and the costs of hospitalizations, procedures, and statin use compared. Cost-effectiveness was estimated as cost per major CV event avoided. There were significantly fewer major CV events in the rosuvastatin group compared with the placebo group (1.04 vs. 1.20 per patient; difference 0.164; 95 CI: 0.075-0.254, P <0.001). The average cost of CV hospitalizations and procedures was significantly lower for those receiving rosuvastatin (£1531 vs. £1769; difference £238; 95 CI: £73-403, P = 0.005); the additional cost of the statin resulted in significantly higher total costs for the rosuvastatin group (£1769 vs. £2072; difference £303; 95 CI: £138-468, P <0.001). Overall, rosuvastatin was found to cost £1840 (95 CI: £562-6028) per major CV event avoided.ConclusionThis economic analysis showed that a significant reduction in major CV events with rosuvastatin led to significantly reduced costs of CV hospitalizations and procedures. The reduction in associated costs for major CV events was found to offset partially (by 44) the cost of rosuvastatin treatment in patients with systolic heart failure.

KW - Cost-effectiveness

KW - Heart failure

KW - Multinational trial

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=72649106603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72649106603&partnerID=8YFLogxK

U2 - 10.1093/eurjhf/hfp172

DO - 10.1093/eurjhf/hfp172

M3 - Article

C2 - 20023047

AN - SCOPUS:72649106603

VL - 12

SP - 66

EP - 74

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 1

ER -